Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle
|
|
- Julian Casey
- 5 years ago
- Views:
Transcription
1 Department of General Services Procurement Division Contract # Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare, Inc., Option Care Enterprises, Inc., River City Pharmacy, Inc. and Walgreens Home Care Inc. Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris Alphanate Alphanate AlphaNine AlphaNine AlphaNine brentuximab vedotin antihemophilic factor/von Willebrand factor complex [human] antihemophilic factor/von Willebrand factor complex [human] Coagulation Factor IX (Human) Coagulation Factor IX (Human) Coagulation Factor IX (Human) 50 mg single-use vial % 250 IU FVIII range vial % 500 IU FVIII range vial % 500 unit vial w/ 10mL diluent 1000 unit vial w/ 10mL diluent 1500 unit vial w/ 10mL diluent single-dose vial % single-dose vial % single-dose vial % Amprya dalfampridine 10 mg 60 count bottle % Apokyn apomorphine HCL injection 10 mg/ml 3 ml cartridge % Aralast NP alpha-1 proteinase inhibitor 0.5 g single-dose vial % Aralast NP alpha-1 proteinase inhibitor 1 g single-dose vial % 200 mcg/1 ml single-dose vial % 300 mcg/1 ml single-dose vial % 25 mcg/1 ml single-dose vial % 40 mcg/1 ml single-dose vial % 60 mcg/1 ml single-dose vial % 100 mcg/1 ml single-dose vial % 150 mcg/0.75 ml single-dose vial % 200 mcg/0.4 ml 300 mcg/0.6 ml 500 mcg/1 ml 25 mcg/0.42ml 40 mcg/0.4 ml 60 mcg/0.3 ml 100 mcg/0.5 ml 150 mcg/0.3ml % % % % % % % % Arzerra ofatumumab 1,000 mg/50 ml single-use vial % 1 of 14
2 ATryn antithrombin [recombinant] 1750 IU vial % Aubagio teriflunomide 7 mg tablet % Avandaryl rosiglitazone maleate and glimepiride 4 mg/1 mg tablet % Avandaryl rosiglitazone maleate and glimepiride 4 mg/2 mg tablet % Avandaryl rosiglitazone maleate and glimepiride 4 mg/4 mg tablet % Avandaryl rosiglitazone maleate and glimepiride 8 mg/2 mg tablet % Avandaryl rosiglitazone maleate and glimepiride 8 mg/4 mg tablet % Avandia rosiglitazone maleate 2 mg tablet % Avandia rosiglitazone maleate 4 mg tablet % Avandia rosiglitazone maleate 8 mg tablet % Avonex Avonex Avonex Baraclue Baraclue Baraclue Baraclue Betaseron interferon beta-1a interferon beta-1a interferon beta-1a 33 mcg (6.6 million intnl units) 30 mcg 30 mcg entecavir 0.5 mg tablet entecavir 0.5 mg tablet entecavir 1 mg tablet single-use vial single-use prefilled syringe Single-Use Prefilled Autoinjector entecavir 0.05 mg/ml oral solution interferon beta-1b 0.3 mg single-use vial % % % % % % % % Cayston aztreonam 75 mg single-use vial % Copaxone glatiramer acetate injection 20 mg w/40 mg of mannitol single-use prefilled syringe % Cystagon cysteamine 50 mg capsules Cystagon cysteamine 150 mg capsules LD - No Access LD - No Access Dacogen decitabine 50 mg single-dose vial % Dificid Enbrel Enbrel Enbrel Enbrel enoxaperi sodium enoxaperi sodium enoxaperi sodium Fidaxomicin etanercept etanercept etanercept 200 mg (bottle of 20) tablet single-use prefilled 50 mg syringe single-use prefilled 25 mg syringe single-use prefilled 50 mg SureClick autoinjector etanercept 25 mg multiple-use vial single-use prefilled 30 mg/0.3 ml syringe single-use prefilled 40 mg/0.4 ml syringe graduated single-use 60 mg/0.6 ml prefilled syringe 2 of % % % % % % % %
3 enoxaperi sodium enoxaperi sodium enoxaperi sodium enoxaperi sodium EPIVIR-HBV EPIVIR-HBV Epogen Epogen Epogen Epogen Epogen Epogen 80 mg/0.8 ml 100 mg/1 ml 120 mg/0.8 ml 150 mg/1 ml lamivudine 100 mg tablet graduated single-use prefilled syringe graduated single-use prefilled syringe graduated single-use prefilled syringe graduated single-use prefilled syringe lamivudine 240 ml oral solution single-dose preservative-free vial 2,000 units/1ml (citrate-buffered) single-dose preservative-free vial 3,000 units/1 ml (citrate-buffered) single-dose preservative-free vial 4,000 units/1 ml (citrate-buffered) single-dose preservative-free vial 10, 000 units/1 ml (citrate-buffered) multiple-dose preserved 10,000 units/1 ml vial multiple-dose preserved 20,000 units/1 ml vial % % % % % % % % % % % % Egrifta tesamorelin 2 mg single-use vial % Erivedge vismodegib 150 mg capsule % Exjade deferasirox 125 mg tablet % Exjade deferasirox 250 mg tablet % Exjade deferasirox 500 mg tablet % Eylea afilbercept injection 2 mg / 0.05 ml single-use vial % Flolan - generic Flolan - generic Forteo epoprostenol 0.5 mg single-dose vial epoprostenol 1.5 mg single-dose vial prefilled delivery device teriparatide injection 2.4 ml (pen) dalteparin sodium injection 2,500 IU / 0.2 ml syringe dalteparin sodium injection 5,000 IU / 0.2 ml syringe dalteparin sodium injection 7,500 IU / 0.3 ml syringe single-dose graduated dalteparin sodium injection 10,000 IU / 1 ml syringe dalteparin sodium injection 12,500 IU / 0.5 ml syringe dalteparin sodium injection 15,000 IU / 0.6 ml syringe dalteparin sodium injection 18,000 IU / 0.72 ml syringe dalteparin sodium injection 95,000 IU / 3.8 ml multiple dose vial 3 of % % % % % % % % % % %
4 Fuzeon Gablofen Gablofen Gablofen Gablofen Gablofen Gablofen enfuvirtide 90 mg single-use vial baclofen injection 50 mcg/1 ml single-use syringe baclofen injection 10,000 mcg/20 ml single-use syringe baclofen injection 10,000 mcg/20 ml single-use vial baclofen injection 20,000 mcg/20 ml single-use syringe baclofen injection 20,000 mcg/20 ml single-use vial baclofen injection 40,000 mcg/20 ml single-use syringe Gablofen baclofen injection 40,000 mcg/20 ml single-use vial Gammagard Liquid Immune Globulin Infusion (human) 10 ml single-use bottle Gammagard Liquid Immune Globulin Infusion (human) 25 ml single-use bottle Gammagard Liquid Immune Globulin Infusion (human) 50 ml single-use bottle Gammagard Liquid Immune Globulin Infusion (human) 100 ml single-use bottle Gammagard Liquid Immune Globulin Infusion (human) 200 ml single-use bottle Gammagard Liquid Immune Globulin Infusion (human) 300 ml single-use bottle Gammagard S/D Gammagard S/D Immune Globulin Intravenous (human) 2.5 g single-use bottle Immune Globulin Intravenous (human) 5 g single-use bottle % % % % % % % % % % % % % % % % Gammagard S/D Immune Globulin Intravenous (human) 10 g single-use bottle % Gammagard S/D LESS IGA Immune Globulin Intravenous (human) 5 g single-use bottle % Gammagard S/D LESS IGA Immune Globulin Intravenous (human) 10 g single-use bottle % Gamunex -C immune globuln injection [human] caprylate chromatography purified 10% 10 ml vial % Gamunex -C immune globuln injection [human] caprylate chromatography purified 10% 25 ml vial % Gamunex -C immune globuln injection [human] caprylate chromatography purified 10% 50 ml vial % Gamunex -C immune globuln injection [human] caprylate chromatography purified 10% 100 ml vial % Gamunex -C immune globuln injection [human] caprylate chromatography purified 10% 200 ml vial % Glassia alpha-1 proteinase inhibitor [human] 1 gm single-dose vial % Gleevec Gleevec H.P. Acthar Gel Hepsera imatinib mesylate imatinib mesylate repository corticostropin adefovir dipivoxil 100 mg tablet % 400 mg tablet % 8 USP/ml 5 ml multi-dose vial % 10 mg Tablet % Hizentra immune globuln subcutaneus [human] 20% 5 ml single-use vial % Hizentra immune globuln subcutaneus [human] 20% 10 ml single-use vial % 4 of 14
5 Hizentra immune globuln subcutaneus [human] 20% 20 ml single-use vial % Hizentra immune globuln subcutaneus [human] 20% 50 ml single-use vial % Humira Humira adalimumab adalimumab 20 mg prefilled glass syringe % 40 mg prefilled glass syringe % Hycamtin (oral) topotecan 0.25 mg capsule % Hycamtin (oral) topotecan 1.0 mg capsule % Iclusig ponatinib 15 mg tablet % Iclusig ponatinib 15 mg tablet % Nexplanon etonogestrel implant 68 mg single implant preloaded in needle % Increlex mecasemin 40 mg multi-dose vial % Inlyta Axitinib 1 mg tablet % Inlyta Axitinib 5 mg tablet % Inton A Inton A Inton A Interferon alfa-2b, recombinant Interferon alfa-2b, recombinant Interferon alfa-2b, recombinant 10 million IU per vial vial % 18 million IU per vial vial % 50 million IU per vial vial % Jakafi ruxolitinib 5 mg tablet % Jakafi ruxolitinib 10 mg tablet % Jakafi ruxolitinib 15 mg tablet % Jakafi ruxolitinib 20 mg tablet % Jakafi ruxolitinib 25 mg tablet % Jetrea ocriplasmin 2.5 mg/ml vial % Kadcyla ado-trastuzumab emtansine 100 mg vial % Kalbitor ecallantide 10 mg/ml vial % KOGENATE FS KOGENATE FS KOGENATE FS KOGENATE FS KOGENATE FS recombinant factor VIII (rfviii) recombinant factor VIII (rfviii) recombinant factor VIII (rfviii) recombinant factor VIII (rfviii) recombinant factor VIII (rfviii) 250 IU vial % 500 IU vial % 1000 IU vial % 2000 IU vial % 3000 IU vial % Krystexxa pegloticase 8 mg/ml vial % Kynamro mipmersen sodium 200 mg/ml pre-filled syringe % Letairis ambrisentan 5 mg tablet % Letairis ambrisentan 10 mg tablet % 5 of 14
6 LEUPROLIDE ACETATE LEUPROLIDE ACETATE 1 mg/0.2 ml vial % Ilaris canakinumab 180 mg vial % Lioresal Lioresal Lioresal Lioresal Lioresal lioresal lioresal lioresal lioresal lioresal 10 mg/20 ml ampules % 10 mg/5 ml ampules % 40 mg/20ml ampules % 10 mg/20 ml ampules % 40 mg/20ml ampules % 30 mg/0.3 ml pre-filled syringe % 40 mg/0.4 ml pre-filled syringe % 60 mg/0.6 ml pre-filled syringe % 80 mg/0.8 ml pre-filled syringe % 100 mg/1 ml pre-filled syringe % 300 mg/ 3 ml vial % 120 mg / 0.8 ml pre-filled syringe % 150 mg / 1 ml pre-filled syringe % Lucentis ranibizumab 0.5 mg vial % Lucentis ranibizumab 0.3 mg vial % Lupron Depot LEUPROLIDE ACETATE 3.75 mg pre-filled syringe % Lupron Depot LEUPROLIDE ACETATE mg pre-filled syringe % Macugen pegaptanib sodium 0.3 mg pre-filled syringe % Makena hydroxyprogesterone caproate 1250 mg multi-dose vial % Matulane procarbazine 50 mg capsule % Mononine MuGard lyophilized concentrate of Factor IX GLY/CARB HOMOPOLY A/POT HYDROX 1000 IU vial % Not avaiable oral solution % Naglazyme galsufase 5 mg / 5 ml vial % Neulasta Neupogen Neupogen Neupogen Neupogen pegfilgrastim filgrastim filgrastim filgrastim filgrastim 6 mg / 0.6 ml pre-filled syringe % 300 mcg/ml vial % 480 mcg /1.6 ml vial % 300 mcg/ 0.5 ml pre-filled syringe % 480 mcg /0.8 ml pre-filled syringe % Nexavar sorafenib 400 mg tablet % ONDANSETRON IV ondansetron 2 mg vial % 6 of 14
7 ONDANSETRON IV ONDANSETRON IV ONDANSETRON IV ONDANSETRON IV ONDANSETRON IV Pegasys Pegasys Pegasys Pegasys ondansetron ondansetron ondansetron ondansetron ondansetron peginterferon alfa-2a peginterferon alfa-2a peginterferon alfa-2a peginterferon alfa-2a 2 mg vial % 2 mg vial % 4 mg vial % 5 mg vial % 6 mg vial % 180 mcg per 1 ml single use vial % 180 mcg per 0.5 ml pre-filled syringe % 180 mcg per 0.5 ml autoinjector % 135 mcg per 0.5 ml autoinjector % Perjeta pertuzumab 420 mg/14 ml vial % Pomalyst pomalidone 1 mg capsule % Pomalyst pomalidone 2 mg capsule % Pomalyst pomalidone 3 mg capsule % Pomalyst pomalidone 4 mg capsule % Procrit Procrit Procrit Procrit Procrit Procrit Procrit Promacta Promacta Promacta Promacta Reclast Remicade Revatio Revatio eltrombopag eltrombopag eltrombopag eltrombopag zoledronic acid infliximab sildenafil sildenafil 2000 Units/ml vial % 3000 Units/ml vial % 4000 Units/ml vial % 10,000 Units/ml vial % 40,000 Units/ml vial % 20,000 Units / 2 ml multi-dose vial % 20,000 Units/ml multi-dose vial % 12.5 mg tablet % 25 mg tablet % 50 mg tablet % 75 mg tablet % 5 mg/100 ml injection % 100 mg vial % 20 mg tablet % 10 mg (12.5 ml) vial % Revlimid lenalidomide 2.5 mg/ml capsule % Revlimid lenalidomide 5 mg capsule % Revlimid lenalidomide 10 mg capsule % 7 of 14
8 Revlimid lenalidomide 15 mg capsule % Revlimid lenalidomide 20 mg capsule % Revlimid lenalidomide 25 mg capsule % RhoGAM PLUS Rho(D) Immune Globulin (Human) 300 μg (1500 IU) prefilled syringe % RhoGAM PLUS Rho(D) Immune Globulin (Human) 50 μg (250 IU) prefilled syringe % RiaSTAP fibrinogen concentrate [human] 1 gm vial % Ribasphere ribavirin 200 mg tablet % Ribasphere ribavirin 400 mg tablet % Ribasphere ribavirin 600 mg tablet % Simponi golimumab 50 mg/0.5 ml prefilled syringe % Simponi golimumab 100 mg/1 ml prefilled syringe % Solesta Dextranomer in stabilized sodium hyaluronate 50 mg/ml, 15 mg/ml glass syringe % Soliris eculizumab 10 mg/ml single-use vial % Somavert pegvisomant 10 mg single-dose vial % Somavert pegvisomant 15 mg single-dose vial % Somavert pegvisomant 20 mg single-dose vial % Sprycel dasatinib 20 mg tablet % Sprycel dasatinib 50 mg tablet % Sprycel dasatinib 70 mg tablet % Sprycel dasatinib 80 mg tablet % Sprycel dasatinib 100 mg tablet % Sprycel dasatinib 140 mg tablet % Stelara ustekinumab 45 mg pre-filled syringe % Stelara ustekinumab 90 mg pre-filled syringe % Stivarga regorafenib 40 mg tablet % Sutent sunitinib malate 12.5 mg capsule % Sutent sunitinib malate 25 mg capsule % Sutent sunitinib malate 50 mg capsule % Synagis palivizumab 50 mg vial % Synagis palivizumab 100 mg vial % Tarceva erlotinib 25 mg tablet % Tarceva erlotinib 100 mg tablet % 8 of 14
9 Tarceva erlotinib 150 mg tablet % Tasigna Nilotinib 150 mg capsule % Tasigna Nilotinib 200 mg capsule % Tecfidera dimethyl fumarate 120 mg capsule % Tecfidera dimethyl fumarate 240 mg capsule % Temodar temozolomide 5 mg capsule % Temodar temozolomide 20 mg capsule % Temodar temozolomide 100 mg capsule % Temodar temozolomide 140 mg capsule % Temodar temozolomide 180 mg capsule % Temodar temozolomide 250 mg capsule % Temodar temozolomide 180 mg vial % Testopel testosterone 78mg subcutaneous implant % Thalomid thalidomide 50 mg capsule % Thalomid thalidomide 100 mg capsule % Thalomid thalidomide 150 mg capsule % Thalomid thalidomide 200 mg capsule % Tobi tobramycin inhalation solution 300 mg / 5 ml ampule % Topi Podhaler tobramycin inhalation powder 28 mg capsule % Tracleer bosentan 62.5 mg tablet : 16.00% Tracleer bosentan 125 mg tablet % Tykerb lapatinib 250 mg tablet % Tysabri natalizumab 300 mg / 15 ml vial % Visudyne verteporfin 15 mg vial % Votrient pazopanib 200 mg tablet % VPRIV velaglucerase alfa 400 units vial % Xalkori crizotinib 250 mg capsule % Xeloda capecitabine 500 mg tablet % Xiaflex coliagenase clostridum histolyticum 0.9 mg vial % Xolair omalizumab 150 mg / 5 ml vial % Xtandi enzalutamide 40 mg capsule % Yervoy ipilimumab 50 mg/10 ml vial % 9 of 14
10 Yervoy ipilimumab 200 mg/40 ml vial % Zelboraf vemurafenib 240 mg tablet % Zoladex goserelin 3.6 mg implant % Zoladex goserelin 10.8 mg implant % Zytiga abiraterone acetate 1000 mg tablet % Travasol amino acid formulas 10% solution % Liposyn soybean oil 20% solution % Non-Specified Product Limited distribution pharmaceuticals 12.50% Non-limited distribution Branded pharmaceuticals 15.50% Non-limited distribution Generic pharmaceuticals 27.00% Infusion 12.00% 10 of 14
11 Department of General Services Procurement Division Contract # Pharmaceutical Acquisitions Section Exhibit G-2 April 30, 2015 Walgreens Specialty Pharmacy LLC, Services Pricing Crescent Healthcare, Inc., Option Care Enterprises, Inc., River City Pharmacy, Inc. and Walgreens Home Care Inc. PER DIEM INJECTABLE AND INFUSION SERVICES HCPCS Description of per diem* Injectable and Infusion Services Rate S9325 Home infusion therapy, pain management infusion $85.00 S9326 Home infusion therapy, continuous (twenty-four hours or more) pain management infusion $85.00 S9327 Home infusion therapy, intermittent (less than twenty-four hours) pain $85.00 S9329 Home infusion therapy, chemotherapy infusions $90.00 S9330 Home infusion therapy, continuous (twenty-four hours or more) chemotherapy infusion $90.00 S9331 Home infusion therapy, intermittent (less than twenty-four hours) chemotherapy infusion $95.00 S9335 Home therapy, hemodialysis $0.00 S9336 Home infusion therapy, continuous anticoagulant infusion therapy (e. g. Heparin) $85.00 S9338 Home infusion therapy, immunotherapy $90.00 S9340 Home therapy; enteral nutrition $10.00 S9341 Home therapy; enteral nutrition via gravity $15.00 S9342 Home therapy; enteral nutrition via pump $20.00 S9343 Home therapy; enteral nutrition via bolus $12.00 S9345 Home infusion therapy, anti-hemophilic agent infusion therapy (e. g. Factor viii) $85.00 S9346 Home infusion therapy, alpha-1-proteinase inhibitor (e. g. prolastin) $85.00 S9347 Home infusion therapy, uninterrupted, long-term, controlled rate intravenous or $90.00 subcutaneous infusion therapy (e. g. Epoprostenol) S9348 Home infusion therapy, sympathomimetic/inotropic agent infusion therapy (e. g. $90.00 dobutamine) S9351 Home infusion therapy, continuous or intermittent anti-emetic infusion therapy $85.00 S9353 Home infusion therapy, continuous insulin infusion therapy $70.00 S9355 Home infusion therapy, chelation therapy $85.00 S9357 Home infusion therapy, enzyme replacement intravenous therapy; (e. g. Imiglucerase) $90.00 S9359 Home infusion therapy, anti-tumor necrosis factor intravenous therapy; (e. g. Infliximab) $90.00 S9361 Home infusion therapy, diuretic intravenous therapy $80.00 S9363 Home infusion therapy, anti-spasmodic therapy $85.00 S9364 Home infusion therapy, total parenteral nutrition (tpn) $ of 14
12 Department of General Services Procurement Division Contract # Pharmaceutical Acquisitions Section Exhibit G-2 April 30, 2015 Walgreens Specialty Pharmacy LLC, Services Pricing Crescent Healthcare, Inc., Option Care Enterprises, Inc., River City Pharmacy, Inc. and Walgreens Home Care Inc. S9365 S9366 S9367 S9368 S9370 S9372 S9373 S9374 S9375 S9376 S9377 S9379 S9490 S9494 S9497 S9500 S9501 S9502 S9503 S9504 S9537 Home infusion therapy, total parenteral nutrition (tpn); one liter per day Home infusion therapy, total parenteral nutrition (tpn); more than one liter but no more than two liters per day Home infusion therapy, total parenteral nutrition (tpn); more than two liters but no more than three liters per day Home infusion therapy, total parenteral nutrition (tpn); more than three liters per day Home therapy, intermittent anti-emetic injection therapy Home therapy; intermittent anticoagulant injection therapy (e. G. Heparin) Home infusion therapy, hydration therapy Home infusion therapy, hydration therapy; one liter per day Home infusion therapy, hydration therapy; more than one liter but no more than two liters per day Home infusion therapy, hydration therapy; more than two liters but no more than three liters per day Home infusion therapy, hydration therapy; more than three liters per day Home infusion therapy, infusion therapy, not otherwise classified Home infusion therapy, corticosteroid infusion Home infusion therapy, antibiotic, antiviral, or antifungal therapy Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours Home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours Home therapy; hematopoietic hormone injection therapy (e. g. Erythropoietin, g-csf, gm.-csf) 12 of 14 $ $ $ $ $65.00 $65.00 $75.00 $75.00 $75.00 $80.00 $80.00 $85.00 $85.00 $ $ $90.00 $95.00 $ $ $ $45.00
13 Department of General Services Procurement Division Contract # Pharmaceutical Acquisitions Section Exhibit G-2 April 30, 2015 Walgreens Specialty Pharmacy LLC, Services Pricing Crescent Healthcare, Inc., Option Care Enterprises, Inc., River City Pharmacy, Inc. and Walgreens Home Care Inc. S9542 S9558 S9559 S9560 S9562 S9590 Home injectable therapy, not otherwise classified Home injectable therapy; growth hormone Home injectable therapy, interferon Home injectable therapy; hormonal therapy (e. g. ; leuprolide, goserelin) Home injectable therapy, palivizumab Home therapy, irrigation therapy (e. g. Sterile irrigation of an organ or anatomical cavity) $65.00 $45.00 $45.00 $65.00 $50.00 $55.00 S9810 CPT Code Home therapy; professional pharmacy services for provision of infusion, specialty drug administration, and/or disease state management, not otherwise classified, per hour Infusion administration up to 2 hours $ $ CPT Code $ Infusion for each additional hour after two hours * "per diem" means infusion services that are bundled together and payment includes professional pharmacy services, patient monitoring, education, and counseling activities, all necessary supplies and equipment, and administrative and other support services. Diluent, Solution, Heparin, Saline, Sterile Water, Etc. are included. Drug products and nursing visits are coded separately from the per diem. 13 of 14
14 Department of General Services Procurement Division Contract # Pharmaceutical Acquisitions Section Exhibit G-2 April 30, 2015 Walgreens Specialty Pharmacy LLC, Services Pricing Crescent Healthcare, Inc., Option Care Enterprises, Inc., River City Pharmacy, Inc. and Walgreens Home Care Inc. COMPOUNDING SERVICES CODE Description of Compounding Services Rate S9430 Pharmacy compounding and dispensing services $25.00 B4189 Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 10 to 51 grams of protein - premix $ B4193 B4197 B4199 B4216 B4220 B4222 B4224 B5000 B5100 Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 52 to 73 grams of protein - premix Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, 74 to 100 grams of protein - premix Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength over 100 grams of protein - premix Parenteral nutrition; additives (vitamins, trace elements, heparin, electrolytes) home mix per day Parenteral nutrition supply kit; premix, per day Parenteral nutrition supply kit; home mix, per day Parenteral nutrition administration kit, per day Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - amirosyn rf, nephramine, renamine - premix Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic - freamine hbc, hepatamine - premix PROFESSIONAL SERVICES $ $ $ $8.77 $9.09 $11.21 $28.39 $13.50 $5.27 CODE Description of Professional Services Rate S9123 Nursing care, in the home; by registered nurse, per hour (use for general nursing care only $ of 14
New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009
STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationRAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
More informationBCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015
Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests
More informationAetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
More informationSPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
More informationMedStar Medicare Choice Pharmacy Services
Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page
More informationPA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationOverview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)
Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally
More informationExclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or
Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not
More informationDescriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin
Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel
More informationJ1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364
G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288
More informationSpecialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs
Specialty Drugs The following is a list of medications that are considered to be specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications
More informationDME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
More informationDME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
More informationSpecialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time.
Specialty Drugs The following is a list of medications that are considered specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications that
More informationPA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131
More informationMEDICAL MANAGEMENT POLICY
PAGE: 1of 8 This Medical policy is not a guarantee of benefits or coverage, nor should it be deemed as medical advice. In the event of any conflict concerning benefit coverage, the employer/member summary
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationDrug Bill As Unit Common Directions Common Day Supply Common Billing Errors Oral Tablets/Capsules
Note: This is a guide for commonly misbilled medications. Please submit the claims according to directions for use indicated on the prescription order. Drug Bill As Unit Common Directions Common Day Supply
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationChemotherapy 101 for Radiation Oncology Workers
Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent
More informationInjections Requiring Prior Authorization
At VIVA Health, we strive to keep our provider network informed of any changes. Most of you may currently obtain prior authorizations for administered injections. Below is a list of injection, infusion,
More informationDrug Name Tier Drug Name Tier
Drug Name Tier Drug Name Tier ABELCET 100 MG/20 ML VIAL 4 ACETYLCYSTEINE 10% VIAL 2 ACETYLCYSTEINE 20% VIAL 2 ACYCLOVIR 1,000 MG/20 ML VIAL 2 ACYCLOVIR 500 MG/10 ML VIAL 2 ADRUCIL 500 MG/10 ML VIAL 2 ALBUTEROL
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationHigh Risk Medications
Department Policy Code: D: MM-5705 Entity: Fairview Health Services Department: Home Infusion Manual: Policies & Procedures Category: Medication Management Subject: High Risk Medications Purpose: To provide
More informationTrusted Health Plan Formulary
2018 Trusted Health Plan Formulary Version 19; Effective 10/22/18 Introduction... 6 The Trusted Health Plan Pharmacy and Therapeutics Committee (P&T)... 6 Notice...6 Preface...6 Product Selection Criteria...
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationLista de medicamentos especializados
Lista de medicamentos especializados Vigencia: 1o. de enero de 2016 A continuación se listan, en orden alfabético, los medicamentos de especialidad recetados más frecuentemente. Los medicamentos de especialidad
More informationPrescription Drug Benefit Rider V
Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationPrescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationSpecialty Pharmacy An Increasing Opportunity for Retail Pharmacy
Specialty Pharmacy An Increasing Opportunity for Retail Pharmacy Presented By: Craig S. Stern, PharmD, MBA, FMCP, CSP April 11, 2015 Attendance Code (Please leave blank) FINANCIAL RELATIONSHIP DISCLOSURES
More informationMEDICAL POLICY: Enteral and Parenteral Nutrition
POLICY: PG0114 ORIGINAL EFFECTIVE: 02/15/07 LAST REVIEW: 08/14/18 MEDICAL POLICY: Enteral and Parenteral Nutrition GUIDELINES This policy does not certify benefits or authorization of benefits, which is
More informationTrusted Health Plan Formulary
2018 Trusted Health Plan Formulary Effective 7/1/2018 Introduction... 6 The Trusted Health Plan Pharmacy and Therapeutics Committee (P&T)... 6 Notice...6 Preface...6 Product Selection Criteria... 6 Formulary
More informationLIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT
LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationMDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
More informationThe revision date appears in the footer of the document. Links within the document are updated as changes occur throughout the year.
An Independent Licensee of the Blue Cross Blue Shield Association. APPENDIX C HOME INFUSION THERAPY MANUAL This appendix to the Business Procedure Manual briefly describes home infusion therapy benefits
More informationLIMITED DISTRIBUTION MEDICATIONS
ACTEMRA IV (USSC can dispense 162 mg PFS) ACTHAR HP ACTIMMUNE ADAGEN ADCETRIS CVS Specialty 1-800-237-2767 1-800-237-2767 ADEMPAS ADVATE ALDURAZYME ALECENSA ALIQOPA ALUNBRIG AMPYRA APOKYN ARALAST NP ARCALYST
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationacromegaly Drugs Covered Uses Exclusion Criteria Required Medical Information Age Restriction Prescriber Restriction Coverage Duration
acromegaly SIGNIFOR, SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML, SOMAVERT SUBCUTANEOUS RECON SOLN 15 MG, 20 MG, 25 MG, 30 MG All medically accepted indications not
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More information2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017
Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq
More information2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018
Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationPHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017
PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on September and December 2017. The following are the recommendations
More informationCPT Service Description Effective Date
Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,
More informationPHARMACY AND THERAPEUTICS COMMITTEE August 2016
PHARMACY AND THERAPEUTICS COMMITTEE August 2016 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on August 23, 2016. The following are the recommendations for the drugs
More informationACAMPROSATE (CAMPRAL)
ACAMPROSATE (CAMPRAL) ACAMPROSATE CALCIUM Creatinine clearance less than 30 PAGE 1 LAST UPDATED 06/2016 ADALIMUMAB (HUMIRA) HUMIRA, HUMIRA PEDIATRIC CROHN'S, HUMIRA PEN, HUMIRA PEN CROHN'S-UC-HS, HUMIRA
More informationINJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]
Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of
More informationFormulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
More informationUPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting
UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting
More informationNATIVA GROUP. Inspired by Innovation and Technology
NATIVA GROUP Inspired by Innovation and Technology INNOVATION & TECHNOLOGY IS OUR PASSION Nativa is a leading group of pharmaceutical companies in Russia. It develops and produces worldclass complex medicines
More informationPPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
More informationFIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) Brand Generic J Code Covered Uses Required Medical Information and
More informationUPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting
UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationSpecialty Drug List - Sorted by Therapeutic Class Developed for the Mississippi Division of Medicaid by Mercer
ANTI-INFECTIVE ABELCET 100 MG/20 ML VIAL 4/1/2017 ANTI-INFECTIVE AMBISOME 50 MG VIAL 4/1/2017 ANTI-INFECTIVE ANCOBON 250 MG CAPSULE 4/1/2017 ANTI-INFECTIVE ANCOBON 500 MG CAPSULE 4/1/2017 ANTI-INFECTIVE
More informationPrior Authorization Program
Prescription Drug List January 2011 Prior Authorization Program The prior authorization program helps us offer broad prescription drug coverage and promotes safe, clinically appropriate drug usage. Under
More informationNICE TA Adherence Check list April Drug Indication NICE Approval Release Date
NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide
More informationSUPPLEMENTARY INFORMATION
Table S1 Therapeutic biologic product approvals, classes and innovation categories: 16 24 Approval year Trade name Active Ingredient(s) Drug class Innovation category Approval date 16 Intron-A Interferon
More informationMDwise Hoosier Care Connect Medical Services that Require Prior Authorization
MDwise Hoosier Care Connect Medical Services that Require Prior Authorization Certain Indiana Health Coverage Programs (IHCP) services require prior authorization (PA) for members enrolled in the Hoosier
More informationEssential Health Benefits Standard Specialty PA and QL List July 2016
Anti-infectives Antiretrovirals, HIV SELZENTRY (maraviroc) Cardiology Antilipemic Pulmonary Arterial Hypertension Central Nervous System Anticonvulsants Depressant Neurotoxins Parkinson's Sleep Disorder
More informationPharmacy Services Request Types
FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare
More informationJ-Code Trade Name Drug Name Required Medical Information
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES Updated: 10/31/2017 J-Code Prior Authorizations & Required Clinical Information Medicaid, Child Health Plus, HealthierLife, Metal-Level J-Code Trade
More informationOriginal Policy Date
MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Coding All Out of Network services Facility to facility ambulance transport
More information1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000
ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN
More informationThe following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Oncology Agents Rx.01.67 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some
More informationMEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT
INFUSION SERVICES & EQUIPMENT Effective Date: August 1, 2017 Review Dates: 10/95, 12/99, 12/01, 11/02, 11/03, 11/04, 10/05, 10/06, 10/07, 10/08, 10/09, 4/10, 4/11, 4/12, 4/13, 5/14, 5/15, 2/16, 2/17, 5/17
More informationNB Drug Plans Formulary Update
Bulletin # 995 March 27, 2019 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective March 27, 2019. Included in this bulletin: Special Authorization Benefit
More informationINJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions
J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation
More informationQuarterly pharmacy formulary change notice
Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table
More informationNICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
More informationMETABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
More informationRelease of the 2017/18 Invitation to Tender
2 November 2017 Release of the 2017/18 Invitation to Tender The 2017/18 Invitation to Tender (2017/18 ITT) has been distributed today. If you have already registered your e-mail address with PHARMAC s
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationDrug Use Evaluation: Physician Administered Drugs (PADs)
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Drug Use Evaluation: Physician Administered
More informationSELF-ADMINISTERED MEDICATIONS LIST
SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Pegasys) Reference Number: CP.CPA.205 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationInjectable Drugs Requiring Pre-Service Approval
Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients
More informationQuarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More informationSASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Health Drug Plan and Extended Benefits Branch April 2006 Bulletin #106 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All
More informationNutrition Therapy. Medical Coverage Policy Enteral/Parenteral EFFECTIVE DATE: POLICY LAST UPDATED: 11/20/2018 OVERVIEW
Medical Coverage Policy Enteral/Parenteral Nutrition Therapy EFFECTIVE DATE: 01 20 2007 POLICY LAST UPDATED: 11/20/2018 OVERVIEW This policy describes the reimbursement for enteral and parenteral nutrition
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationSelf-Injected Medications and Disposal Recommendations
Actimmune (interferon gamma 1b) Apokyn (apomorphine hydrochloride) Arixtra (fondaparinux) Avonex (interferon beta 1a) Betaseron (interferon beta 1b) Copaxone (glatiramer acetate) Edex (alprostadil) InterMune
More information